Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103312 | 0.89 | HTR2A (0.51) | MEN1KMT2AHSD17B10HTR2AHTR2C | |
| SCHEMBL6504509 | 0.75 | MEN1 (0.50) | MEN1KMT2AHSD17B10HTR2AHTR2C | |
| SCHEMBL428079 | 0.75 | HSD17B10 (0.50) | MEN1KMT2AHSD17B10HTR2AHTR2C | |
| SCHEMBL31319181 | 0.75 | MEN1 (0.50) | MEN1KMT2AHSD17B10HTR2AHTR2C | |
| SCHEMBL224258 | 0.72 | KDM4E (0.46) | MEN1KMT2AHSD17B10HTR2AHTR2C | |
| SCHEMBL1919190 | 0.71 | HTR2A (0.46) | MEN1KMT2AHSD17B10HTR2AHTR2C | |
| SCHEMBL28459559 | 0.70 | MEN1 (0.45) | MEN1KMT2AHSD17B10HTR2AHTR2C | |
| SCHEMBL28465952 | 0.70 | MEN1 (0.45) | MEN1KMT2AHSD17B10HTR2AHTR2C | |
| SCHEMBL28459535 | 0.70 | MEN1 (0.45) | MEN1KMT2AHSD17B10HTR2AHTR2C | |
| SCHEMBL998088 | 0.69 | KDM4E (0.81) | MEN1KMT2AHSD17B10HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134657-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIDAZINE BASED COMPOUNDS AND USE THEREOF AS PKR INHIBITORS | PROTEKT THERAPEUTICS LTD. (IL) | 2024-06-27 | — | — | WO | disclosed |
| EP-4376837-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | Immunyx Pharma Ltd. (IL) | 2024-06-05 | — | — | EP | disclosed |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | BIOND BIOLOGICS LTD. (IL) | 2024-05-09 | — | — | US | disclosed |
| CN-117651568-A | Intracellular delivery compositions | 比昂生物制剂公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-4326332-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | Biond Biologics Ltd. (IL) | 2024-02-28 | — | — | EP | disclosed |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| WO-2023233413-A1 | eIF4G1-eIF1 INHIBITORS AND USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-07 | — | — | WO | disclosed |
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-06-29 | — | — | US | disclosed |
| WO-2023112038-A1 | NEUTROPHIL EXOCYTOSIS INHIBITORS | IMMUNYX PHARMA LTD. (IL) | 2023-06-22 | — | — | WO | disclosed |
| WO-2009128918-A1 | COMBINATION THERAPY USING A SOLUBLE HYALURONIDASE AND A BISPHOSPHONATE | HALOZYME, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-7582794-B2 | Process for the preparation of substituted 2-(phenoxymethyl)benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| WO-2009082437-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009009117-A2 | CHEMOENZYMATIC PROCESSES FOR PREPARATION OF LEVETIRACETAM | BIOVERDANT, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1699748-B1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7238835-B2 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| EP-1699748-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-09-13 | — | — | EP | disclosed |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| WO-2005061427-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | APOL1, APOB, LIPA | MEN1 1100/4885KMT2A 4245/4885HSD17B10 378/4885 |
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | CYP2B6, CYP1B1, CYP4B1 | MEN1 415/4885KMT2A 1106/4885HSD17B10 521/4885 |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | LCAT, CD47, PHOSPHO1 | MEN1 762/4885KMT2A 419/4885HSD17B10 1006/4885 |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | ACTB, CHERP, EEA1 | MEN1 2434/4885KMT2A 4267/4885HSD17B10 3810/4885 |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | CYP2B6, CYP1B1, CYP4B1 | MEN1 415/4885KMT2A 1106/4885HSD17B10 521/4885 |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | IGF2BP1, IGF2BP2, IGF2BP3 | MEN1 855/4885KMT2A 1585/4885HSD17B10 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.